Page One
Bayer, Aventis to Merge
Berkeley-based Bayer has announced plans to merge its unit that makes blood-plasma products with a rival owned by Aventis of France.
Bayer said it had signed a letter of intent to take a “substantial majority interest” and management control of the venture, which will have annual sales of more than $2 billion. Bayer also would have an option to buy the stake held by Aventis at a later date.